Minireviews
Copyright ©The Author(s) 2023.
World J Clin Cases. Apr 6, 2023; 11(10): 2168-2180
Published online Apr 6, 2023. doi: 10.12998/wjcc.v11.i10.2168
Table 3 Sensitivity of Omicron variants to therapeutic monoclonal antibodies
mAb (s)FDA EUATarget on SOmicron variant
BA.1
IC50
BA.2
IC50
Bamla/Etese Yes BRD or SReduction in activity vs control approximately 1000-fold (highly resistant)> 10000 ng/mLReduction in activity vs control approximately 1000-fold (highly resistant)> 10000 ng/mL
Casir/Imdev YesBRD Reduction in activity vs control approximately 1000-fold (highly resistant)> 10000 ng/mLReduction in activity vs control approximately 1000-fold (highly resistant)> 10000 ng/mL
SotroYes BRD Median fold reduction in susceptibility 4.0 (IQR: 2.6 to 6.9)Median 276 ng/mL (IQR: 163 to 423)Median fold reduction in susceptibility 17 (IQR: 13 to 30)Median 1250 ng/mL (IQR: 567 to 1456)
Cilag/TixagYes BRD Median fold reduction in susceptibility 86 (IQR:27 to 151). The FDA recommended that the dosage for each mAb in this combination be increased 300 mg and administered intramuscularlyMedian 256 ng/mL (IQR: 170 to 750) Median fold reduction in susceptibility 5.4 (IQR: 3.7 to 6.9). Nearly complete restoration BA.2 susceptibility to cilgavimabMedian 44 ng/mL (IQR: 27 to 73)
BebteYes BRD Median fold reduction in susceptibility 1.0 (IQR: 0.7 to 1.4) Bebtelovimab is the only mAb active against the current dominant circulating Omicron variant; in non- hospitalized adults, bebtelovimab may be used as an alternative therapy when no preferred therapy (e.g., nirmatrelvir/ritonavir, remdesivir) available Median 2.6 ng/mL (IQR: 1.8 to 5.0)Median fold reduction in susceptibility 1.0 (IQR: 0.7 to 1)Median 4.0 ng/mL (IQR: 0.8 to 5.0)
RegdaNoBRDDisplayed little residual activity NADisplayed little residual activity NA
AmubaNoBRDDisplayed little residual activity NADisplayed little residual activityNA
RomluNoBRDRetained partial activity NADisplayed little residual activityNA
AdintNoBRDRetained partial activityNANA